378 studies found for:    "HIV Seronegativity" [CONDITION]
Show Display Options
Rank Status Study
21 Completed A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203);   Biological: Aluminum hydroxide;   Biological: MF59;   Biological: rgp120/HIV-1MN
22 Completed A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: gp160 Vaccine (Immuno-AG)
23 Completed A Study to Test the Safety of Three Experimental HIV Vaccines
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: HIV p24/MF59 Vaccine;   Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65);   Biological: rgp120/HIV-1 SF-2
24 Completed Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)
Conditions: HIV Infections;   Pregnancy;   HIV Seronegativity
Intervention: Biological: gp160 Vaccine (MicroGeneSys)
25 Withdrawn Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: Aluminum hydroxide;   Biological: QS-21;   Biological: MN rsgp120/HIV-1
26 Completed Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa
Conditions: HIV Infections;   HIV Seronegativity
Intervention:
27 Completed A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: Env 2-3
28 Active, not recruiting Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
Conditions: HIV Seronegativity;   HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59;   Biological: DNA-C2 + MVA-C;   Biological: DNA-C2 + MVA-C + gp140/MF59
29 Completed Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission
Conditions: HIV Infections;   Vitamin A Deficiency;   HIV Seronegativity
Intervention: Drug: Vitamin A
30 Completed Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: MN rgp120/HIV-1 and A244 rgp120/HIV-1
31 Completed Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC-HIV (vCP205)
32 Completed Botanical/Drug Interactions in HIV: Glucuronidation
Condition: HIV Seronegativity
Intervention: Drug: silymarin
33 Recruiting Pre-exposure Prophylaxis Accessibility Research and Evaluation 2
Conditions: PrEP Uptake;   HIV Seronegativity
Intervention: Behavioral: Informed Risk Score
34 Completed A Study of Male Rectal Samples in Preparation for Future Rectal Microbicide Trials
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Procedure: Flexible Sigmoidoscopy;   Procedure: Rectal Biopsy
35 Completed Long-Term Effects of HIV Exposure and Infection in Children
Conditions: HIV Infections;   HIV Seronegativity
Intervention:
36 Completed
Has Results
Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
Conditions: Kaposi's Sarcoma;   HIV Infections;   HIV Seronegativity
Intervention: Biological: Bevacizumab
37 Completed Peer Mentors for Adolescents in HIV Affected Families
Conditions: Adolescent Behavior;   Health Behavior;   HIV Seronegativity
Intervention: Behavioral: Peer mentoring program
38 Terminated Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Drug: Tenofovir DF
39 Completed A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: rgp120/HIV-1MN;   Biological: rgp120/HIV-1 SF-2;   Biological: Placebo version of  rgp120/HIV-1MN;   Biological: Placebo version of rgp120/HIV-1SF2
40 Completed A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: MTP-PE/MF59;   Biological: Env 2-3

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years